{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:12:26Z","timestamp":1776064346483,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of age on oncological outcomes in a large contemporary cohort of patients with non\u2010muscle\u2010invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette\u2013Gu\u00e9rin (BCG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We performed an Institutional Review Board\u2010approved retrospective study analysing patients with NMIBC treated with adequate BCG at our institution from 2000 to 2020. Adequate BCG was defined as per United States Food and Drug Administration (FDA) guidelines as being receipt of at least five of six induction BCG instillations with a minimum of two additional doses (of planned maintenance or of re\u2010induction) of BCG instillations within a span of 6\u2009months. The study's primary outcome was to determine if age &gt;70\u2009years was associated with progression to MIBC cancer or distant metastasis. The cumulative incidence method and the competing\u2010risk regression analyses were used to investigate the association of advanced age (&gt;70\u2009years) with progression, high\u2010grade (HG) recurrence and cancer\u2010specific mortality (CSM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, data from 632 patients were analysed: 355 patients (56.2%) were aged \u226470\u2009years and 277 (43.8%) were &gt;70\u2009years. Age &gt;70\u2009years did not adversely affect either cumulative incidence of progression or HG recurrence (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.067 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.644, respectively). On competing\u2010risk regression analyses, age &gt;70\u2009years did not emerge as an independent predictor of progression or HG recurrence (sub\u2010standardised hazard ratio [SHR] 1.57, 95% confidence interval [CI] 0.87\u20132.81,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.134; and SHR 1.05, 95% CI 0.77\u20131.44,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.749). Not unexpectedly, patients in the older group did have higher overall mortality (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) but not CSM (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.057).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Age &gt;70\u2009years was not associated with adverse oncological outcomes in a large contemporary cohort of patients receiving adequate intravesical BCG for NMIBC. BCG should not be withheld from older patients seeking for bladder sparing options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16127","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T20:28:07Z","timestamp":1689280087000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of age &gt;70\u2009years on oncological outcomes in patients with non\u2010muscle\u2010invasive bladder cancer treated with Bacillus Calmette\u2013Gu\u00e9rin"],"prefix":"10.1111","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7011-0537","authenticated-orcid":false,"given":"Roberto","family":"Contieri","sequence":"first","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"},{"name":"Humanitas University  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Grajales","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Shen","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Hensley","sequence":"additional","affiliation":[{"name":"Department of Urology University of Kentucky  Lexington KY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-7763","authenticated-orcid":false,"given":"Kelly","family":"Bree","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-8399","authenticated-orcid":false,"given":"Niyati","family":"Lobo","sequence":"additional","affiliation":[{"name":"Department of Urology Guy's and St Thomas NHS Foundation Trust  London United Kingdom of Great Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela M.","family":"Nogueras\u2010Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00481-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.03.024"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.05.033"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.040"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001633"},{"key":"e_1_2_10_11_1","unstructured":"U.S Department of Health and Human Services Food and Drug Administration.BCG\u2010unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. 13.2018. Available at:https:\/\/www.fda.gov\/media\/101468\/download#:~:text=For%20the%20purposes%20of%20this completion%20of%20adequate%20BCG%20therapy"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09076.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02555.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-017-9682-z"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05370.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2022.05.034"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq241"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016223"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03130-1"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003315.05"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602102"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:02:36Z","timestamp":1761753756000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/bju.16127"],"URL":"https:\/\/doi.org\/10.1111\/bju.16127","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"2023-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}